| Trial ID: | L3226 |
| Source ID: | NCT02043886
|
| Associated Drug: |
Acarbose
|
| Title: |
Acarbose, Postprandial Hypotension and Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Postprandial Hypotension
|
| Interventions: |
DRUG: Acarbose|DRUG: Placebo
|
| Outcome Measures: |
Primary: Heart rate, Heart rate will be measured continuously by Finometer during the Meal Tests. Each Meal Test will take approximately 4 hours, continuously during Meal Test; about 4 hours|Blood pressure, Blood pressure will be measured continuously by Finometer during each of the Meal Tests (approximately 4 hours), Continuously during Meal Tests (approximately 4 hours)|Middle cerebral artery velocity, Middle cerebral artery velocity will be measure continuously by transcranial doppler during the Meal Tests (approximately 4 hours), continuously during Meal Tests (approximately 4 hours)|Serum glucose, Serum glucose will be measured using a YSI (Yellow Spring Instruments) Stat 2300 Blood Glucose Analyzer, Every 15 minutes during Meal Tests|Serum insulin, Serum insulin levels will be collected every 15 minutes during the Meal Tests (approximately 4 hours) and analyzed by Elisa (enzyme linked immunoabsorbant) assays., Every 15 minutes during Meal Tests (approximately 4 hours)|Serum peptides: GIP (gastric inhibitory polypeptide) and GLP-1 (glucagon like peptide), Serum peptides will be collected every 15 minutes for the duration of the Meal Tests (approximately 4 hours) and analyzed by Elisa (enzyme linked immunoabsorbant) assays., Every 15 minutes during Meal Tests (approximately 4 hours)|Catecholamines, Serum insulin levels will be collected every 15 minutes during the Meal Tests (approximately 4 hours) and analyzed by Elisa (enzyme linked immunoabsorbant) assays., Continuously during Meal Test (approximately 4 hours) |
|
| Sponsor/Collaborators: |
Sponsor: University of British Columbia | Collaborators: Canadian Diabetes Association
|
| Gender: |
ALL
|
| Age: |
OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-06
|
| Completion Date: |
2014-05
|
| Results First Posted: |
|
| Last Update Posted: |
2017-06-28
|
| Locations: |
VITALiTY Research Centre, Vancouver, British Columbia, V5Z1M9, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02043886
|
